Inflectra Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Inflectra market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to several factors, including the rising prevalence of chronic diseases, increased acceptance of biosimilars, a higher incidence of autoimmune diseases, growing healthcare expenditure, and the increasing number of patent expirations.

Growth during the market's forecast period can be driven by the rising demand for homecare options, a growing emphasis on personalized medicine, increased attention to rural healthcare, a shift towards preventive healthcare, and the expanding use of digital health tools. Key trends in the forecast period include the use of single-use bioreactors, patient education platforms, global regulatory harmonization, artificial intelligence-driven drug development, and innovative regulatory approvals.

The growing prevalence of autoimmune diseases is expected to drive the growth of the inflectra market in the future. Autoimmune diseases occur when the immune system erroneously attacks healthy cells, causing inflammation and damage to tissues and organs. The rise in autoimmune diseases can be attributed to factors such as changes in diet, exposure to pollutants, lifestyle habits, and climate change. This increase in autoimmune conditions is boosting demand for effective treatments such as inflectra, which plays a crucial role in managing diseases such as rheumatoid arthritis and Crohn's disease by inhibiting tumor necrosis factor-alpha (TNF-α) to reduce inflammation. For example, in September 2023, the IBD Clinical and Research Centre, a Canadian organization focused on improving the lives of patients with Crohn’s disease and ulcerative colitis, reported that over 320,000 Canadians are living with inflammatory bowel disease (IBD). With a prevalence rate of 825 per 100,000 people, IBD is expected to rise annually by 2.44%, with 1.1% of the Canadian population, or approximately 470,000 people, projected to have IBD by 2035. Thus, the increasing prevalence of autoimmune diseases is driving the inflectra market's growth.

The increasing number of clinical trials is also expected to fuel the growth of the inflectra market. Clinical trials are studies involving human participants to assess the effects of new medical interventions, such as drugs, devices, and treatments, on health outcomes. These trials are critical for determining the safety and efficacy of treatments before they receive widespread approval. The growth in clinical trials can be attributed to the rising demand for innovative treatments, advances in medical research, the need for diverse participant representation, and the urgency to address unmet medical needs in various populations. This trend positively impacts inflectra by generating substantial data on its safety and effectiveness, thus strengthening its market position and boosting demand for it as a treatment for autoimmune diseases. For example, according to a report from the Association of British Pharmaceutical Industry (ABPI), the total number of clinical trials initiated in the UK increased by 4.3% from 394 trials in 2021 to 411 in 2022. Therefore, the expanding number of clinical trials is supporting the growth of the inflectra market.

A leading company in the inflectra market is focused on developing innovative products, such as subcutaneous infliximab biosimilars, to provide a more convenient and effective maintenance treatment option for patients with inflammatory bowel disease. The subcutaneous infliximab biosimilar is an injectable form of infliximab that offers a more convenient method for treating autoimmune diseases. For instance, in October 2023, Celltrion USA, a U.S.-based subsidiary of the biopharmaceutical company Celltrion, announced the FDA approval of ZYMFENTRA (infliximab-dyyb), the first and only subcutaneous formulation of infliximab for the maintenance treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC) in adults. This new subcutaneous formulation ensures stable, elevated serum infliximab levels, providing a more flexible and convenient administration option for both patients and healthcare providers. The approval is significant as it addresses the day-to-day challenges of managing inflammatory bowel disease and gives patients greater control over their treatment regimen.

The key company operating in the inflectra market is Celltrion Inc.

Europe was the largest region in the inflectra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inflectra report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the inflectra market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Inflectra, also known by its generic name infliximab-dyyb, is a biosimilar to Remicade (infliximab) and functions as a tumor necrosis factor (TNF) inhibitor. It is widely used to treat a range of autoimmune disorders, including rheumatoid arthritis, Crohn's disease, and ulcerative colitis. This monoclonal antibody specifically targets and blocks TNF-alpha, a crucial pro-inflammatory protein involved in immune responses.

The primary patient groups for inflectra include both pediatric and adult patients. Pediatric patients are children and adolescents under 18 who may suffer from autoimmune conditions such as Crohn's disease or ulcerative colitis. Inflectra is used to treat a variety of conditions, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and others. It is distributed through various channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies.

The Inflectra market research report is one of a series of new reports that provides Inflectra market statistics, including Inflectra industry global market size, regional shares, competitors with Inflectra market share, detailed Inflectra market segments, market trends, and opportunities, and any further data you may need to thrive in the Inflectra industry. This Inflectra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The inflectra market consists of sales of lyophilized powder and intravenous infusion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.